Proteins Services

Rokote Laboratories Finland Ltd. has selected 3PBIOVIAN as their CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate expressing a modified spike protein of severe acute respiratory coronavirus 2 (SARS-CoV-2).

Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced their combination.

Paris, February 1, 2024 - Biovian and 3P Biopharmaceuticals (“3P”), two leading biologics Contract Development and Manufacturing Organizations (CDMOs), announced today their combination to establish a new pan-European leader in their field. Backed by their common shareholder, Keensight Capital, one of the leading private equity funds dedicated to pan-European Growth Buyout[[1]] investments, the combination of Biovian and 3P further extends the group’s value proposition to address complex customer needs across the entire development cycle.

[1] Growth Buyout: investment in profitable, private companies experiencing strong growth, in minority or majority positions, with or without leverage, using a flexible approach tailored to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies or provide historic shareholders with liquidity.

Rokote Laboratories Finland Ltd. has selected 3PBIOVIAN as their CDMO partner for GMP manufacturing of adenovirus type 5 (Ad5) vector-based candidate.